Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prime Medicine, Inc.PRME · Entity 5281 | Director | June 05, 2026 | June 08, 2026 |
| Rallybio CorpRLYB · Entity 6838 | Director | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prime Medicine, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2036-06-05 | Direct | 75,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Rallybio Corp
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,562 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Exercise / conversion · Acquired 3,562 · Balance 3,562 |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2035-05-13 | Direct | 0 |
Reported balance
After 2026-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-16 · Exercise / conversion · Disposed 3,562 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 21:42 UTC | Rallybio Corp RLYB · Entity 6838 | Exercise / conversionOption (Right to Buy) · Derivative | 3,562 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001193125-26-395755 · ownership.xml · derivative · entry 2 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,562 shares Expires 2035-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 21:42 UTC | Rallybio Corp RLYB · Entity 6838 | Exercise / conversionCommon Stock | 3,562 | $2.38 | $8,477.56 |
DisclosureSEC source: 0001193125-26-395755 · ownership.xml · nonDerivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:14 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001628280-26-041560 · wk-form4_1780949685.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 8 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $7.68 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 7 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 39,062 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 6 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,062 Underlying: Common Stock · 39,062 shares Expires 2033-06-14 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 39,062 | Not disclosed Strike: $14.83 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 5 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,062 shares Expires 2033-06-14 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 9,006 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 4 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,006 Underlying: Common Stock · 9,006 shares Expires 2032-10-19 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 9,006 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 3 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,006 shares Expires 2032-10-19 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 13,510 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 2 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,510 Underlying: Common Stock · 13,510 shares Expires 2031-11-24 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 13,510 | Not disclosed Strike: $10.54 | Not disclosed |
DisclosureSEC source: 0001894562-25-000045 · wk-form4_1754440974.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,510 shares Expires 2031-11-24 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 22:13 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001628280-25-029769 · wk-form4_1749161355.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:09 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001739410-25-000086 · wk-form4_1747343353.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-05-13 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:58 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001894562-24-000036 · wk-form4_1718398722.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 12, 2025 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:03 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001739410-24-000087 · wk-form4_1715979779.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-15 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:47 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 39,062 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001894562-23-000023 · wf-form4_168695205505085.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,062 Underlying: Common Stock · 39,062 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 14, 2024 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:19 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 12,353 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0000899243-23-013393 · doc4.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,353 Underlying: Common Stock · 12,353 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 17, 2024 or the date of the Company's 2024 Annual Meeting of Stockholders. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:27 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 9,482 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0000899243-23-001046 · doc4.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,482 Underlying: Common Stock · 9,482 shares Expires 2033-01-03 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2023. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:31 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 9,006 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-22-026824 · wf-form4_166638426814621.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,006 Underlying: Common Stock · 9,006 shares Expires 2032-10-19 F1 · derivative.exercise_date: The shares underlying this option shall vest in three equal annual installments beginning on September 13, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:48 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 26,880 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0000899243-22-027631 · doc4.xml · derivative · entry 1 Chung Wendy · CIK 0001922605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,880 Underlying: Common Stock · 26,880 shares Expires 2032-08-01 F1 · derivative.exercise_date: The option is granted under the Company's 2021 Equity Incentive Plan. The option vests in three equal annual installments beginning on August 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.